茵栀黄颗粒联合人免疫球蛋白治疗新生儿ABO溶血性黄疸的疗效观察

目的探讨茵栀黄颗粒联合人血丙种球蛋白治疗新生儿ABO溶血性黄疸的临床疗效。方法选取2014年5月—2016年5月月在合肥市滨湖医院接受治疗的ABO溶血性黄疸患儿80例,根据治疗方法的不同分为对照组(40例)和治疗组(40例)。对照组患儿静脉滴注静注人免疫球蛋白(p H 4)治疗,剂量为1 g/(kg·d)。治疗组在对照组的基础上口服茵栀黄颗粒,1 g/次,3次/d。两组患儿均治疗3 d。比较两组患儿治疗前后临床疗效、血清指标变化以及新生儿神经行为(NBNA)和GESELL评分。结果治疗后,对照组和治疗组的总有效率分别为80.00%、97.50%,两组总有效率比较差异具有统计学意义(P0.05)。治疗后,两组患儿血清总胆红素(TBIL)水平显著降低,同组比较差异具有统计学意义(P0.05);且治疗后治疗组患儿血清TBIL水平显著优于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,两组患儿NBNA评分均显著升高,同组比较差异具有统计学意义(P0.05)。治疗后治疗组NBNA和GESELL评分升高幅度显著好于对照组,两组比较差异具有统计学意义(P0.05)。结论茵栀黄颗粒联合人血丙种球蛋白治疗新生儿ABO溶血性黄疸具有很好的临床效果,可有效降低胆红素水平,促进患儿生长发育,具有一定的临床推广应用价值。

Clinical observation of Yinzhihuang Granules combined with human immunoglobulin in treatment of neonatal ABO hemolytic jaundice

Objective To investigate the clinical efficacy of Yinzhihuang Granules combined with human immunoglobulin in treatment of neonatal ABO hemolytic jaundice. Methods Children (80 cases) with ABO hemolytic jaundice in Hefei Binhu Hospital from May 2014 to May 2016 were divided into control (40 cases) and treatment (40 cases) groups based on different treatments. Children in the control group were iv administered with human immunoglobulin (pH 4) for iv injection, 1 g/(kg·d). Patients in the treatment group were po administered with Yinzhihuang Granules on the basis of the control group, 1 g/time, three times daily. Patients in two groups were treated for 3 d. After treatment, the clinical efficacy, serum indexes, NBNA, and GESELL scores in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 80.00% and 97.50%, respectively, and there was difference between two groups (P < 0.05). After treatment, the serum TBIL levels in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). The serum TBIL levels in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the NBNA scores in two groups were significantly increased, and the difference was statistically significant in the same group (P < 0.05). After treatment, the NBNA and GESELL scores in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Yinzhihuang Granules combined with human immunoglobulin has good clinical effect in treatment of neonatal ABO hemolytic jaundice, can effectively reduce the bilirubin level and promote the growth and development of children, which has a certain clinical application value.